Patents Examined by Deepak Rao
  • Patent number: 9550760
    Abstract: The present invention relates generally to the use of compounds to treat a variety of disorders, diseases and pathologic conditions and more specifically to the use of substituted indol-5-ol derivatives to modulate protein kinases and for treating protein kinase-mediated diseases.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: January 24, 2017
    Assignee: NantBioScience, Inc.
    Inventor: Chunlin Tao
  • Patent number: 9546175
    Abstract: The invention relates to novel inhibitors of phosphodiesterase 1 (PDE1), useful for the treatment of diseases or disorders characterized by disruption of or damage to certain cGMP/PKG mediated pathways (e.g., in cardiac tissue). The invention further relates to pharmaceutical composition comprising the same and methods of treatment of cardiovascular disease and related disorders, e.g., congestive heart disease, atherosclerosis, myocardial infarction, and stroke.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: January 17, 2017
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Peng Li, Hailin Zheng, Jun Zhao, Lawrence P. Wennogle
  • Patent number: 9540334
    Abstract: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
    Type: Grant
    Filed: July 29, 2015
    Date of Patent: January 10, 2017
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Rajinder Singh, Ankush Argade, Donald G. Payan, Susan Molineaux, Sacha J. Holland, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Catherine Sylvain, Hui Li, Alexander B. Rossi
  • Patent number: 9533982
    Abstract: Disclosed are negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: January 3, 2017
    Assignee: Vanderbilt University
    Inventors: P. Jeffrey Conn, Craig W. Lindsley, Kyle A. Emmitte, Andrew S. Felts
  • Patent number: 9533959
    Abstract: The present invention relates to the novel regioselective syntheses of 2,4-disubstituted pyrimidines through sequential nucleophilic aromatic substitutions.
    Type: Grant
    Filed: February 15, 2016
    Date of Patent: January 3, 2017
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jean-Damien Charrier, Michael Edward O'Donnell
  • Patent number: 9533991
    Abstract: Disclosed herein are amido compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: January 3, 2017
    Assignee: PHARMACYCLICS LLC
    Inventors: Wei Chen, Longcheng Wang, Zhaozhong J. Jia
  • Patent number: 9518046
    Abstract: The invention relates to the preparation and use of new aminopyrimidine derivatives as drug candidates in free form or in pharmaceutically acceptable salt form and formulations thereof for the modulation of a disorder or disease which is mediated by the activity of the PI3K enzymes. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of disorders or diseases, such as disorders of immunity and inflammation in which PI3K enzymes play a role in leukocyte function, and hyperproliferative disorders associated with PI3K activity, including but not restricted to leukemias and solid tumors, in mammals, especially humans.
    Type: Grant
    Filed: March 15, 2015
    Date of Patent: December 13, 2016
    Assignees: CALITOR SCIENCES, LLC, SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Ning Xi, Liang Wang, Zuping Wu, Xuejin Feng, Yanjun Wu
  • Patent number: 9512114
    Abstract: The invention relates to the preparation and use of new aminopyrimidine derivatives as drug candidates in free form or in pharmaceutically acceptable salt form and formulations thereof for the modulation of a disorder or disease which is mediated by the activity of the PI3K enzymes. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of disorders or diseases, such as disorders of immunity and inflammation in which PI3K enzymes play a role in leukocyte function, and hyperproliferative disorders associated with PI3K activity, including but not restricted to leukemias and solid tumors, in mammals, especially humans.
    Type: Grant
    Filed: March 15, 2015
    Date of Patent: December 6, 2016
    Assignees: CALITOR SCIENCES, LLC, SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Ning Xi, Liang Wang, Tingjin Wang
  • Patent number: 9505667
    Abstract: There is provided a method for deuterating an aromatic compound having aromatic hydrogens. The method includes the steps: (a) providing a liquid composition including deuterium oxide having dissolved or dispersed therein the aromatic compound and a transition metal catalyst; and (b) heating the liquid composition at a temperature of 120° C. or greater, and a pressure of 50 psi or greater, for a period of 24 hours or less, to form a deuterated aromatic compound.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: November 29, 2016
    Assignee: E I DU PONT DE NEMOURS AND COMPANY
    Inventors: Michael Henry Howard, Jr., David P Bellon, David P Dickson, Jeffrey A Merlo
  • Patent number: 9504683
    Abstract: The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTC”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: November 29, 2016
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Sara Hadida Ruah, Mark Miller, Jinglan Zhou, Brian Bear
  • Patent number: 9505792
    Abstract: Cidofovir is obtained in different forms, including amorphous cidofovir, crystalline anhydrous cidofovir, crystalline cidofovir monohydrate, and crystalline cidofovir dihydrate, including various polymorphs.
    Type: Grant
    Filed: March 4, 2015
    Date of Patent: November 29, 2016
    Assignee: Johnson Matthey Public Limited Company
    Inventors: George Scott Wilson, Angela Barkley, Jurjus Jurayj
  • Patent number: 9499492
    Abstract: The present invention relates to 4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amine derivatives containing a sulfoximine group of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).
    Type: Grant
    Filed: November 11, 2013
    Date of Patent: November 22, 2016
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Ulrich Lücking, Dirk Kosemund, Rolf Bohlmann, Arne Scholz, Philip Lienau, Gerhard Siemeister, Ulf Bömer
  • Patent number: 9499493
    Abstract: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
    Type: Grant
    Filed: September 22, 2015
    Date of Patent: November 22, 2016
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Rajinder Singh, Ankush Argade, Donald G. Payan, Susan Molineaux, Sacha J. Holland, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Catherine Sylvain, Hui Li, Alexander B. Rossi
  • Patent number: 9498479
    Abstract: Provided herein are dihydropyrimidine compounds and their pharmaceutical applications, especially for use in treating and preventing HBV diseases. Specifically, provided herein are compounds having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein the variables of the formulas are as defined in the specification. Also provided herein is the use of the compounds having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof for treating and preventing HBV diseases.
    Type: Grant
    Filed: November 18, 2014
    Date of Patent: November 22, 2016
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Yingjun Zhang, Xinchang Liu, Zhifu Zou, Jinsheng Liang, Siegfried Goldmann, Qingyun Ren
  • Patent number: 9499534
    Abstract: The invention provides certain thiazole-substituted aminopyrimidine compounds of the Formula (I) (I), or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R5, R6, and the subscripts r, s, and t are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk).
    Type: Grant
    Filed: April 22, 2014
    Date of Patent: November 22, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Kenneth L. Arrington, Byron DuBois, John S. Debenham, Ping Liu, Alan B. Northrup, Jason W. Szewczyk, Liping Wang, Ming Wang
  • Patent number: 9487508
    Abstract: The present patent application discloses at least the compounds according to Formula I or Formula Ib shown below, or pharmaceutically acceptable salts thereof, wherein ring B, JB, n, JD, J, o, X, RC and RA are as described herein.
    Type: Grant
    Filed: September 19, 2013
    Date of Patent: November 8, 2016
    Assignee: IRONWOOD PHARMACEUTICALS, INC.
    Inventors: Takashi Nakai, Nicholas Robert Perl, Joel Moore
  • Patent number: 9487523
    Abstract: The invention encompasses a novel process for making piperidinone carboxamide indane and azainane derivatives, which are CGRP receptor antagonists useful for the treatment of migraine, utilizing a highly effective spiroacid synthesis.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: November 8, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Kevin M. Belyk, Edward Cleator, Shen-Chun Kuo, Peter Emmanuel Maligres, Bangping Xiang, Nobuyoshi Yasuda, Jianguo Yin
  • Patent number: 9487534
    Abstract: In addition to containing and protecting the viral genome, the capsid (protein shell) of hepatitis B virus (HBV) plays critical roles in the viral life cycle including regulation of intracellular trafficking and nucleic acid metabolism. Substituted pyrimidine modulators of the assembly of the HBV capsid structure and methods for their use are described.
    Type: Grant
    Filed: August 2, 2012
    Date of Patent: November 8, 2016
    Assignees: Scripps Research Institute, A Not-for-Profit Public Benefit Corporation of California, Indiana University Research and Technology Corporation
    Inventors: Adam Zlotnick, M. G. Finn
  • Patent number: 9481654
    Abstract: The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.
    Type: Grant
    Filed: February 17, 2015
    Date of Patent: November 1, 2016
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Hui Li, Ankush Argade, Kin Tso, Sambaiah Thota, David Carroll, Arvinder Sran, Robin Cooper, Rajinder Singh, Somasekhar Bhamidipati, Vanessa Taylor, Esteban Masuda
  • Patent number: 9481667
    Abstract: Solid forms of chemical compounds that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein. Also provided herein are processes for preparing compounds, solid forms thereof, and pharmaceutical compositions thereof.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: November 1, 2016
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Daniel G. Genov, Louis Grenier, Andrew B. Hague, Alexander Redvers Eberlin, Ludovic Sylvain Marc Renou, Susana Del Rio Gancedo